Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics Post published:January 11, 2021 Post category:Press Release
CYBIN Provides Update on Patent Filings & Development of Therapeutics Program Post published:January 6, 2021 Post category:Press Release
Cybin Announces First Quarter Financial Results of Clarmin Explorations Inc. Post published:December 29, 2020 Post category:Press Release
CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings Post published:December 14, 2020 Post category:Press Release
CYBIN Signs Definitive Agreement to Acquire Adelia Therapeutics as Part of its Commitment to Strategic Growth Post published:December 7, 2020 Post category:Press Release
Cybin Goes Public on the NEO Exchange Under Symbol CYBN Post published:November 10, 2020 Post category:Press Release
Cybin (CYBN) to Go Public on NEO Exchange on or about Nov 10th Post published:November 5, 2020 Post category:News
Oregon and DC Decriminalisation Initiative Successes: The Psychedelics Sector Reacts Post published:November 4, 2020 Post category:Interview/News
Cybin Corp Establishes a Firm Foothold in the Psychedelic Sector with Historic CAD$45 Million Raise Post published:October 30, 2020 Post category:Analysis/Editorial
Cybin Raises $45 Million, Inches Closer to NEO Listing Post published:October 19, 2020 Post category:Press Release